ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

Circulating tumour DNA-guided adjuvant atezolizumab prolongs disease-free and overall survival in patients with ...

A large meta-analysis suggests radical cystectomy offers better survival outcomes compared with trimodality therapy for patients with muscle-invasive bladder cancer. Radical cystectomy (RC) for muscle ...

An innovative new treatment option for bladder cancer, recently approved by the U.S. Food and Drug Administration, has been performed for the first time in Maryland.

Aug 12 (Reuters) - Pfizer (PFE.N), opens new tab said on Tuesday its cancer drug Padcev, in combination with Merck's (MRK.N), opens new tab Keytruda, significantly improved survival rates in patients ...

Throughout October, CURE highlighted research developments and evolving treatment strategies that continue to shape cancer ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...

BERLIN -- Patients with cisplatin-ineligible bladder cancer had huge reductions in clinical events and cancer death when treated with a novel combination therapy before and after surgery, according to ...

Topline results from the IMvigor011 trial show that ctDNA-guided adjuvant atezolizumab improves survival in patients with MIBC. Adjuvant atezolizumab in patients who are ctDNA-positive after radical ...